Immunogenicity of a 20-valent pneumococcal conjugate vaccine in adults 18 to 64 years old with medical conditions and other factors that increase risk of pneumococcal disease

• Main Authors: Charu Sabharwal (Author), Vani Sundaraiyer (Author), Yahong Peng (Author), Lisa Moyer (Author), Todd J. Belanger (Author), Bradford D. Gessner (Author), Luis Jodar (Author), Kathrin U. Jansen (Author), William C. Gruber (Author), Daniel A. Scott (Author), Wendy Watson (Author)
• Format: Book
• Published: Taylor & Francis Group, 2022-11-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

The aim of this post hoc analysis was to describe the immunogenicity of the 20-valent pneumococcal conjugate vaccine (PCV20) in adults with chronic medical conditions or smoking that place them at increased risk of developing pneumococcal disease. Data from 2 phase 3, randomized, active-controlled,...